Abstract:Background:The advent of immune checkpoint inhibitors (ICI) has radically changed the paradigm of care for patients with non-small cell lung cancer (NSCLC). However, response patterns of tumors treated with immunotherapies may differ compared with conventional chemotherapeutic agents or targeted therapies, and accurate assessment of the response can be radiologically challenging. Most of the current immune-related response criteria are designed to identify pseudoprogression but not hyperprogressive disease (HPD). The objective of the current analysis was to explore the biomarkers which can distinguish different patterns of responses of in ICI-treated NSCLC patients.Methods:Among patients with NSCLC treated with ICI at our Institute, at least 2 CT scans before ICI therapy (baseline and the most recent scan before baseline) and 1 CT scan during treatment were mandatory for radiological evaluation. The tumor growth rate (TGR) was calculated from the sum of the largest diameters of the target lesions as per RECIST version 1.1 to evaluate the percentage increase in tumor volume per month. HPD was defined as delta TGR exceeding 50%. Pseudoprogression was defined as initial progression, followed by complete response or partial response or stable disease. Flow cytometry was used to obtain CD3+CD8+ T cells from peripheral blood mononuclearcells. Immunosequencing of the CDR3 regions of TCRb chains was performed. TCR clonality is compared pre-therapy to initial evaluation. Results:A total of 51 patients were included in our study. By the time of first radiological assessment,11 cases were defined as Responders (21.6%), 16 patients with Stable Disease (31.4%), 24 cases defined as Progressors (47.1%).Six patients meet the criteria for HPD. During the following treatment, 3 of 24 progressors were confirmed to have pseudoprogression. The degree of TCR clonality change ranged from 2.17 to 0.64 times in all patients. Clinical response is significantly correlated with increased repertoire clonality of CD3+CD8+ T cells (P = 0.01). Among three kinds of disease progression, pseudoprogression showed an increase in TCR clonality than true progression patients (1.47 vs. 0.79, P=0.01). Interestingly, the decrease of TCR clonality is greater in patients developed typical PD than in HPD (-0.19 vs. -0.05, P=0.03). Our further analysis showed that Patients who demonstrated RECIST-PD with an increased clonality had a longer median PFS compared to patients with a declined clonality (8.9 versus 2.4 months, p = 0.01).Conclusion: The results demonstrate that the change in clonality of CD3+CD8+ T cell receptor can differentiate atypical patterns of progression in patients with NSCLC treated with ICI. Results of this TCR test performed at regular intervals during ICI treatment reflect tumor biology and have potential as a powerful biomarker to predict long-term response. Citation Format: Jiefei Han, Zhijie Wang, Yuqi Wang, Si Chen, Hua Bai, Jianchun Duan, Jie Wang. Dynamic clonality of T cell receptor differentiate atypical progression in NSCLC patients treated with PD-1/PD-L1inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3247.

Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin.

Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer

Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting

Progressive Disease with Mixed Response After Immunotherapy in Non-Small Cell Lung Cancer

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors

Case Report: Tumor Microenvironment Characteristics in a Patient with HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease.

Immune-inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD-L1 ≥50% metastatic non-small cell lung cancer receiving first-line immunotherapy

Hyperprogressive disease in patients receiving immune checkpoint inhibitors

Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors

Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors

[Biological function of ribonucleic acid: recent results of virus research].

Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy

High HPK1+PD-1+TIM-3+CD8+ T cells infiltration predicts poor prognosis to immunotherapy in NSCLC patients

Stereochemical aspects of sesquiterpene biosynthesis

Real-World Outcomes and Prognostic Factors among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors As First-Line Therapy

Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05

Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice

Abstract 3247: Dynamic Clonality of T Cell Receptor Differentiate Atypical Progression in NSCLC Patients Treated with PD-1/PD-L1inhibitors

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors